Jazz Pharmaceuticals (JAZZ) Faces A Succession Test Following An Undervalued View
Jazz Pharmaceuticals (JAZZ) drew fresh attention after Executive Vice President and Chief Commercial Officer Samantha Pearce notified the company of her planned retirement, prompting a formal search for her successor.
Short-term momentum has cooled for Jazz Pharmaceuticals, with the share price down 7.3% over the past week and 9.5% over the last month. However, the year-to-date share price return of 26.2% and 1-year total shareholder return of 61.3% suggest longer term optimism that this pullback may reflect investors reassessing near term execution risk rather than abandoning the broader earnings story.
Scan how other hand-picked biopharma players with recent leadership shifts are trading by running the 20 high quality undiscovered gems alongside Jazz Pharmaceuticals today.
After a 7.3% pullback in a week and a 61.3% total return over 1 year, Jazz Pharmaceuticals now sits at a familiar crossroads. Do you pay up for resilience, or wait and hope for a cheaper entry that never arrives?
Most Popular Narrative: 26% Undervalued
Against the last close at $218.42, the most followed narrative pegs Jazz Pharmaceuticals’ fair value at $294.27. This frames the recent pullback as a valuation gap rather than a broken thesis.
Expected expansion of Ziihera across additional HER2 driven tumors, including biliary tract, colorectal, lung and early or metastatic breast cancer, following the raised US$3b to US$5b peak sales outlook, could add new oncology revenue streams and support higher long term earnings power.
See why 35 investors see Jazz Pharmaceuticals as 26% undervalued.
Result: Fair Value of $294.27 (UNDERVALUED)
Still, the Jazz Pharmaceuticals story can be knocked off course if key oncology trials disappoint, or if patent expiries and generic rivals bite harder than expected.
Find out about the key risks to this Jazz Pharmaceuticals narrative.
Next Steps
Sentiment around Jazz Pharmaceuticals is clearly mixed, and that is exactly why your own work matters most. Check the numbers, weigh both the concern around 1 or more risks and the optimism around 1 or more potential rewards, then ground your view in the 5 key rewards and 2 important warning signs.
Hunting For Your Next Idea Beyond Jazz Pharmaceuticals?
Do not stop at one compelling story. Use the Simply Wall St screener to line up a watchlist of stocks that genuinely earn a place in your portfolio.
- Target value opportunities that combine quality with a discount by scanning a curated set of underpriced businesses through the 28 high quality undervalued stocks.
- Protect your downside first by focusing on financially resilient companies using the 31 resilient stocks with low risk scores before capital chases them away from attractive levels.
- Get ahead of the crowd by searching for fundamentally strong companies that are still flying under most radars with the 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com